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1. Introduction 
Transcription factors are proteins that bind DNA and either promote or block gene 
transcription. The activating transcription factor/cyclic AMP response element binding 
(ATF/CREB) family of transcription factors are involved in various cellular processes, 
including cell stress responses, cell survival, and cell growth. In this chapter, we will first 
give an overview of the transcriptional regulation of oncogenesis, followed by a brief 
summary of the roles of ATF/CREB family members in breast cancer. After this, we will 
describe the structure of ATF/CREB family members and then go into detail concerning 
each ATF/CREB family member that has a function relevant to breast cancer. Finally, we 
will end the chapter with some forward-looking remarks on ATF/CREB-based breast cancer 
therapeutics. 
2. Transcriptional regulation in breast cancer 
Transcription factors play an important role in breast cancer tumorigenesis and progression. 
For example, ETS1, ELF3, PDEF, PEA3, HIF-1, and MYC are all transcription factors that are 
overexpressed in breast cancer (Kurpios and others 2003). Overexpression of MYC in MCF7 
human non-metastatic breast cancer cells causes those cells to display a metastatic-like 
phenotype (de Launoit and others 2000). The transcriptional targets of PEA3 include MMP1, 
MMP3, MMP9, vimentin, and ICAM-1, genes that are involved in breast cancer cell invasion 
and migration (de Launoit and others 2000). Other transcription factors involved in breast 
cancer include snail, which blocks E-cadherin transcription (Cano and others 2000); 
CBP/p300, a transcriptional co-activator involved in HER2 expression (Wang and others 
2001); STAT6, which blocks the immune response to breast cancer (Sinha and others 2005); 
and Fra-1, whose overexpression leads to increased invasion in breast cancer (Mizutani and 
others 2004). Like PEA3, Runx2 is also involved in breast cancer metastasis, specifically, 
metastasis to bone (Shore 2005). Its targets include collagenase-3 and BSP, which are 
upregulated in metastatic breast cancer cells (Shore 2005). Since it is well known that tumors 
can become hypoxic, it is not surprising that HIF-1 is overexpressed in primary breast 
tumors (Kimbro and Simons 2006). Its best known target is VEGF, an inducer of 
angiogenesis (Kimbro and Simons 2006). MYC is amplified and overexpressed in breast 
cancer (Chen and Olopade 2008). Its amplification is correlated with tumor progression and 
poor prognosis (Chen and Olopade 2008). MYC binds MAX to form a heterodimer that 
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induces the transcription of genes such as MTA1, which is involved in transformation; 
PEG10, which plays a role in proliferation; hTERT; and VEGF (Chen and Olopade 2008). In a 
transgenic mouse model, overexpression of MYC in the mammary epithelium caused breast 
cancer to develop after eight months (Rose-Hellekant and Sandgren 2000). Similar to MYC, 
MYB is amplified in hereditary breast cancer (Kauraniemi and others 2000). MYB is 
involved in ER-dependent breast cancer cell proliferation (Ramsay and Gonda 2008). Its 
targets are anti-apoptotic genes, such as MYC, cyclin A1, and BCL2 (Ramsay and Gonda 
2008). 
Several transcription factors are constitutively active in breast cancer, including the aryl 
hydrocarbon receptor, STAT3, and NF-κB (Pensa, Watson, Poli 2009; Schlezinger and others 
2006; Vogel and Matsumura 2009). The aryl hydrocarbon receptor targets CYP1B1, a P450 
enzyme (Schlezinger and others 2006). STAT3 is correlated with increased breast cancer cell 
survival, cytoskeletal reorganization, and migration (Pensa, Watson, Poli 2009). It activates 
HGF (Elliott and others 2002), cyclin D1, MYC, and bcl-XL (Silva and Shupnik 2007). In 
addition, it blocks the transcription of p21, which is an inhibitor of cell cycle progression 
(Silva and Shupnik 2007). Constitutively active NF-κB, which is found in more than 90% of 
breast cancer (Vogel and Matsumura 2009), leads to breast cancer tumors that are hormone-
independent (Wysocki and Wierusz-Wysocka 2010) and drug resistant (Garg and others 
2003). 
Many transcription factors act as tumor suppressors, including FoxP3, KLF10, p53, and 
GATA3. FoxP3, an X-linked breast cancer tumor suppressor, blocks HER2 expression 
(Medema and Burgering 2007). KLF10 is a transcription factor whose expression is inversely 
correlated with breast cancer stage (Subramaniam and others 2010). Its targets are BARD1 
and Smad2, which are tumor suppressors (Subramaniam and others 2010). The tumor 
suppressor, p53, is mutated in about 26% of all breast cancers (Patocs and others 2007). It 
transactivates p21 and can also transcriptionally activate Bax1, leading to apoptosis 
(Ingvarsson 1999). GATA3, the most highly expressed transcription factor in the mammary 
epithelium (Kouros-Mehr and others 2008), is normally involved in luminal epithelial cell 
differentiation (Chou, Provot, Werb 2010). However, it is lost during cancer progression 
(Chou, Provot, Werb 2010). Indeed, decreased GATA3 expression is correlated with a worse 
prognosis, characterized by less differentiated, ER- cancer (Chou, Provot, Werb 2010). 
The steroid hormone receptors, which are ligand-activated nuclear receptors that act as 
transcription factors, deserve special mention when it comes to breast cancer. The estrogen 
receptor (ER) and the progesterone receptor (PR) are overexpressed in many breast cancers. 
This has led to the development of anti-estrogens and aromatase inhibitors for breast cancer 
treatment. Besides leading to breast cancer tumorigenesis, ER also induces breast cancer 
progression (Carroll and Brown 2006), and it is not only overexpression, but mutations and 
alternative splicing that can cause breast cancer (Toran-Allerand 2004). ER targets include 
PR, c-jun (Fang, Chen, Weigel 2009), p52/TFF1, MYC, cyclin D1, and BCL2 (Welboren and 
others 2009). Like ER, PR also contributes to breast cancer. The progesterone receptor causes 
cells to enter S phase and mediates anchorage-independent growth in response to progestin 
(Daniel, Knutson, Lange 2009). PR targets include MYC (Lange 2008), p21, EGFR, SGK, 
Tissue Factor, Muc-1, HB-EGF, and IRS-1 (Daniel, Knutson, Lange 2009). In addition to ER 
and PR in breast cancer, it is interesting to note that the androgen receptor (AR) protects 
against breast cancer. AR expression is correlated with a better prognosis (Yeap, Wilce, 
Leedman 2004), and mutations in the AR DNA-binding domain have been found in male 
breast cancer (MacLean, Warne, Zajac 1995). 
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3. ATF/CREB transcription factors in breast cancer 
Like the transcription factors described in the previous section, the ATF/CREB family of 
transcription factors plays a role in breast cancer and may prove to be an effective 
therapeutic target. Some family members, such as ATF1, are protective against breast cancer, 
while the roles of others, such as ATF2 and ATF3, remain controversial. Still other family 
members, such as ATF4, ATF5, and CREB, promote breast cancer pathology (Table 1). These 
latter may be the most promising targets for intervention, since inhibiting their production 
or activation could block tumor growth and metastasis. The following sections will focus on 
the structure and function of individual ATF/CREB transcription factors. 
4. Structure of ATF/CREB family members 
The ATF/CREB family consists of a group of transcription factors that all contain an N-
terminal DNA-binding domain and a C-terminal basic leucine zipper (B-ZIP) domain that 
binds other B-ZIP transcription factors to form homo- and heterodimers (Vinson and others 
2002). ATF and CREB were both originally named in 1987 and were later found to bind to 
the same consensus sequence (Hai and Hartman 2001). The DNA-binding consensus 
sequence for this family is GTGACGT A/C A/G, which is found in the promoter region of 
target genes (Hai and Hartman 2001). Specificity is achieved by homo- and 
heterodimerization and epigenetic mechanisms, such as DNA methylation (Hai and 
Hartman 2001). For example, ATF1 forms heterodimers with CREM Ia and CREM IIb 
(Newman and Keating 2003). Likewise, ATF2, ATF4, and ATF5 all form heterodimers with 
C/EBPǄ (Newman and Keating 2003). Based on the dimers that they form, ATF/CREB 
transcription factors are able to regulate the transcription of many target genes involved in 
breast cancer pathology and suppression. 
5. ATF1 
Several groups have identified ATF1 targets in both mice and humans. For example, Torti’s 
group at Wake Forest found that ATF1 aids in the transcription of H ferritin in mouse 
fibroblasts (Tsuji, Torti, Torti 1998). Perhaps more relevant to breast cancer, ATF1 increases 
the transcription of H-2Dd, a major histocompatibility complex (MHC) class I gene (Ishiguro, 
Brown, Meruelo 1997). The transcription of such a gene could allow the immune system to 
tag breast cancer cells for destruction. Besides its effects on the immune system, ATF1 may 
also play a role in breast cancer via its regulation of steroidal hormone synthesis. Clem et al. 
(Clem, Hudson, Clark 2005) showed that ATF1 binds the steroidal acute regulatory protein 
(StAR) promoter, although they failed to determine whether this association activates or 
blocks transcription. Regardless of ATF1’s effect, regulation of StAR, an enzyme necessary 
for estradiol synthesis, may play an important role in preventing breast cancer because a 
longer time of exposure to estradiol (menarche to menopause) is correlated with increased 
breast cancer risk. In addition to its actions on H-2Dd and StAR in mice, ATF1 blocks 
thrombospondin1 transcription in human thyroid cancer cells (Ghoneim and others 2007). 
Whether or not this effect translates to breast cancer cells has yet to be confirmed. Most 
relevant to breast cancer is that BRCA1 activates ATF1 (Houvras and others 2000). BRCA1 
and BRCA2 act as tumor suppressor genes, and they often contain mutations in breast 
cancer. Houvras et al. (Houvras and others 2000) found that wild type (wt) BRCA1 bound 
ATF1, causing transcription of a luciferase reporter gene. Such a finding strongly suggests 
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Table 1. The roles of ATF/CREB family members in breast cancer. 
that ATF1 protects against breast cancer. The fact that ATF1 associates with BRCA1, 
activates H-2Dd, and may block StAR synthesis indicates that it acts as a tumor suppressor 
in breast cancer. On the other hand, its blockage of thrombospondin would suggest that it 
plays a pro-tumorigenic role. However, the work with thrombospondin has not been 
verified in vivo, and such an effect may only occur in thyroid cancer cells. Unfortunately, 
 
ATF/CREB 
Family Member stegraTrecnaC tsaerB ni eloR
H ferritin (Tsuji, 1998)
H-2D d (Ishiguro, 1997)
StAR (Clem, 2005)
Thrombospondin 1 (Ghoneim, 2007)
Collagen, type X, α1 (Tsuchimochi, 2010) 
MMP13 (Tsuchimochi, 2010)
Cyclin A (van Dam, 2001)
Aromatase (Deb, 2006)
MMP2 (Song, 2006)
COX2 (Subbaramaiah, 2002)
Cyclin D1 (Lee, 1999)
Maspin (Maekawa, 2008)
IFNγ (Xue, 2005)
FoxP3 (Liu, 2009)
Fibronectin (Yin, 2010)
Snail (Yin, 2010)
Twist (Yin, 2010)
Slug (Yin, 2010)
av integrin (Yin, 2010)
β6 integrin (Yin, 2010)
E-cadherin (Yin, 2010)
Increased malignancy Osteocalcin (St-Arnaud, 2007)
Type I collagen (Ameri, 2008)
TRB3 (Ameri, 2008)
E-selectin (Ameri, 2008)
Asparagine synthetase (Ameri, 2008)
RANKL (Ameri, 2008)
VEGF (Ameri, 2008)
GADD34 (Fels, 2006)
CHOP (Fels, 2006)
Gamma-synuclein (Hua, 2009)
LAMP3 (Mujcic, 2009)
Phosphoenolpyruvate carboxykinase 2 (Pascual, 2008) 
Aldolase B (Pascual, 2008)
ID1 (Gho, 2008)
Egr-1 (Li, 2009; Liu, 2011)
Mcl-1 (Sheng, 2010)
Bcl-2 (Dluzen, 2011)
Hsp27 (Wang, 2008)
CYP2B6 (Pascual, 2008)
Aromatase (Brown, 2010)
Bcl-2 (Dong, 1999)
Malignancy
Cell Survival
Unclear
Unclear
Most likely supresses tumor formation
ATF2 
ATF1 
Angiogenesis
CREB
ATF5 
ATF4 
ATF3 
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very few studies have been performed on the role of ATF1 in breast cancer. Important future 
studies will elucidate the effects of ATF1 on immunity and hormone synthesis in both 
normal and neoplastic breast cells, as well as its role in breast cancer in vivo. 
6. ATF2 
The exact role of ATF2 in breast cancer is unclear. Targets for ATF2 have been found in both 
chickens and mice. One such target, Col10a1 (collagen, type X, ǂ1), mediates chondrocyte 
differentiation (Tsuchimochi and others 2010). ATF2 also increases the transcription of 
matrix metalloproteinase 13 (MMP13), which may help facilitate breast cancer metastasis 
(Tsuchimochi and others 2010). Matrix metalloproteinases degrade the basement membrane 
during the metastatic cascade. So the fact that ATF2 enhances the transcription of MMP13 
indicates that it may increase the likelihood of tumor metastasis. In addition, Jun-ATF2 
dimers have been shown to lead to the transcription of cyclin A, which increases cell 
proliferation (van Dam and Castellazzi 2001), providing further evidence for a possible 
oncogenic role for ATF2. 
In primary human adipose fibroblasts obtained from breast cancer patients, co-culture with 
malignant epithelial cells increased the levels of phosphorylated ATF2 (pATF2) found at the 
I.3/II promoter of aromatase, the enzyme responsible for estrogen synthesis (Deb and others 
2006). Co-culture with the malignant cells also increased binding of pATF2 to itself, 
C/EBPǃ, and CBP (Deb and others 2006). The fact that ATF2 aids in the transcription of a 
gene that increases estrogen levels makes it seem pro-tumorigenic. Furthermore, pATF2 has 
been shown to aid in the transcription of matrix metalloproteinase 2 (MMP2), which 
increases migration in H-Ras-transformed MCF10A human breast epithelial cells (Song and 
others 2006). Such activity indicates that ATF2 may play a role in breast cancer metastasis, if 
not oncogenesis. ATF2 also forms a complex with c-Jun and c-Fos that mediates HER2’s 
induction of cyclooxygenase-2 (COX2), which itself may be carcinogenic (Subbaramaiah and 
others 2002). The fact that ATF2 is downstream of HER2 lends strong support to the notion 
that it is involved in some breast cancers. In addition, Lee et al. (Lee and others 1999) found 
that v-src causes ATF2 and CREB to bind the CRE/ATF site of the cyclin D1 gene, leading to 
transcription of cyclin D1 in MCF7 human breast cancer cells. Cyclin D1 inactivates the 
retinoblastoma tumor suppressor (RB), predisposing cells to malignancy (Hunter and Pines 
1994; Sherr 1994). So ATF2’s role here would again indicate that it acts as an oncogene. 
In contrast to the above-mentioned studies, which describe ATF2 as contributing to a 
malignant phenotype, several groups have characterized it as protective against breast 
cancer. For instance, Maekawa et al. found that knockout of ATF2 increased cell number, 
decreased apopotosis, and increased the number of v-K-ras-induced colonies in mouse 
embryonic fibroblasts (MEF’s) (Maekawa and others 2007). Plus, knockdown of ATF2 
decreased levels of one of its targets, the breast cancer suppressor, maspin, in the mammary 
tumors of ATF2+/- mice (Maekawa and others 2007; Maekawa and others 2008). Such 
findings would support the argument that ATF2 inhibits breast cancer formation. Along 
those lines, ATF2 has been shown to bind to the proximal element of interferon gamma 
(IFNǄ) in MCF7 cells (Xue, Firestone, Bjeldanes 2005). Increased production and secretion of 
IFNǄ by breast cancer cells could help the immune system destroy malignant cells before 
they spread, thereby inhibiting tumor growth and preventing metastasis. In a similar vein, 
decreased ATF2 levels have been shown to diminish the level of FoxP3, a breast cancer 
tumor suppressor (Liu and others 2009), lending further support to the idea that ATF2 
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inhibits breast cancer. However, studies in a wide range of human breast cancer cell lines 
are needed in order to definitively determine ATF2’s role in breast cancer. 
7. ATF3 
Like ATF2, ATF3’s role in breast cancer remains poorly delineated, although recent evidence 
characterizes it as an oncogene that may be involved in metastasis. Yin et al. (Yin and others 
2010) found that ATF3 mediates the TGFǃ-induced increase in the expression of fibronectin, 
twist, snail, and slug in MCF10C1a1 human breast cancer cells. In addition, ATF3 
overexpression led to an increase in av and ǃ6 integrins, as well as increased migration in 
MCF10C1a1 cells (Yin and others 2010). Furthermore, ATF3 caused a decrease in E-cadherin 
expression, as well as other genetic and morphological changes characteristic of the 
epithelial to mesenchymal transition (EMT) (Yin and others 2010). All of these findings 
support the idea tha ATF3 mediates EMT and metastasis in breast cancer. In addition, ATF3 
also supports oncogenesis, as overexpression of ATF3 in MCF10C1a1 cell that were injected 
into nude mice increased the incidence of tumor formation (Yin and others 2010). Similarly, 
overexpression of ATF3 in the mammary gland myoepithelial cells of transgenic mice 
caused squamous metaplasia in nulliparous females and led to the formation of mammary 
tumors in animals that had given birth twice (Wang and others 2008). This is perhaps the 
most convincing evidence that ATF3 acts as an oncogene in breast cancer. 
All of the above findings on ATF3 seem to establish it as an oncogene and metastasis 
promoter, yet some doubt remains. Einbond et al. (Einbond and others 2007) found that 
actein decreased cell proliferation in mouse embryonic fibroblasts (MEF’s) in an ATF3-
dependent manner. However, this finding may pertain only to MEF’s and not to breast 
cancer cells. Other groups have found that the anti-neoplastic agents, doxorubicin and 
gemcitabine, increase ATF3 levels in human breast cancer cell lines (Hernandez-Vargas and 
others 2007; Mallory and others 2005). However, it remains unclear whether these drugs are 
acting through ATF3 or ATF3 is upregulated as part of an intracellular compensatory 
response. The best evidence that we have today suggests that ATF3 acts to promote 
tumorigenesis and metastasis. However, more studies must be conducted in order to 
confirm these results. 
8. ATF4 
Unlike ATF2 and ATF3, ATF4 is clearly pro-tumorigenic in breast cancer. Perhaps most 
telling, increased ATF4 levels have been found in human tumors compared to normal tissue 
(Ameri and Harris 2008), and several ATF4 targets indicate an oncogenic phenotype. Targets 
of ATF4 include osteocalcin (St-Arnaud and Elchaarani 2007), type I collagen, TRB3, E-
selectin, and asparagine synthetase (Ameri and Harris 2008). More relevant to cancer, ATF4 
acts as an activating transcription factor for RANKL, which activates Akt/PKB, an anti-
apoptotic enzyme (Ameri and Harris 2008). Such activity in the breast would favor the 
formation of cancer. Besides RANKL expression, ATF4 also induces VEGF transcription 
(Ameri and Harris 2008), which can lead to angiogenesis at the sites of primary and 
secondary tumors, allowing hypoxic tumors to reach normoxia. In addition, ATF4 likely 
protects tumor cells form hypoxia by increasing the transcription of GADD34 and CHOP, 
which protect cells from hypoxic damage (Fels and Koumenis 2006). The center of a tumor 
often becomes hypoxic, and ATF4 may play a role in preventing hypoxia-induced cancer 
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cell death. Although ATF4 benefits the organism during development, bone formation, and 
stress, it can also act in a sinister fashion by aiding in tumor formation. 
Indeed, several studies have shown a link between ATF4 levels and a more malignant 
genotype in human breast cancer cells. For instance, decreased ATF4 levels have been 
shown to cause a decrease in gamma-synuclein levels in T47D breast cancer cells (Hua and 
others 2009). Such a correlation with gamma-synuclein, which is up-regulated in advanced 
breast cancer (Bruening and others 2000), may indicate that ATF4 mediates breast tumor 
progression. Furthermore, hypoxia has been shown to increase LAMP3 levels in MCF7 cells 
via the action of ATF4 (Mujcic and others 2009). This further implicates ATF4 in tumor 
progression and metastasis, as LAMP3 has been shown to play a role in metastasis (Mujcic 
and others 2009). Interestingly, this finding suggests that hypoxic tumors may be more 
likely to metastasize than those with an adequate blood supply. Finally, ATF4 has been 
shown to mediate the osteopontin-induced increase in VEGF expression in MDA-MB-231 
cells (Chakraborty, Jain, Kundu 2008). Since VEGF secretion leads to the recruitment of 
endothelial cells as part of the process of angiogenesis, this would suggest that ATF4 is able 
to help primary and secondary breast tumors survive, at least once osteopontin has 
activated it. Clearly, overexpression or constitutive activation of ATF4 causes breast cancer 
cells to become more malignant. 
9. ATF5 
Like ATF4, ATF5 contributes to a malignant phenotype. Targets of ATF5 include aldolase B 
(Pascual and others 2008), ID1 (Gho and others 2008), Egr-1 (Li and others 2009; Liu and 
others 2011), Mcl-1 (Sheng and others 2010), Bcl-2 (Dluzen and others 2011), and 
phosphoenolpyruvate carboxykinase 2 (PEPCK) (Pascual and others 2008). Up-regulation of 
PEPCK, a glycolytic enzyme, could indicate that ATF5 plays a role in the Warburg effect, in 
which cancer cells use aerobic glycolysis to generate ATP rather than oxidative 
phosphorylation. It is thought that this use of a less efficient means of producing ATP allows 
proliferating cells to more efficiently produce other needed metabolites, such as acetyl-CoA 
and NADPH (Vander Heiden, Cantley, Thompson 2009). In addition to increasing PEPCK 
production, ATF5 activates the transcription of heat shock protein 27 (Hsp27), which blocks 
apoptosis (Wang, Lin, Zhang 2007). Such an anti-apoptotic mechanism may lead to breast 
cancer oncogenesis. Furthermore, ATF5 has been shown to increase the level of CYP2B6 in 
human hepatoma cells (Pascual and others 2008). This P450 enzyme metabolizes 
cyclophosphamide, which is used to treat breast cancer. Thus, by inducing an enzyme that 
degrades cyclophosphamide, ATF5 may contribute not only to oncogenesis, but also to drug 
resistance. Based on the target genes that it up-regulates, such as Hsp27 and CYP2B6, ATF5 
should be pro-tumorigenic in breast cancer. 
Indeed, our recent studies indicate that ATF5 induces transcription of the pro-mitogenic 
early growth response factor (Egr-1) gene in MCF7 human breast cancer cells (Li and others 
2009; Liu and others 2011). In addition, ATF5 also binds the Bcl-2 P2 promoter and 
transactivates Bcl-2, an anti-apoptotic gene, leading to breast cancer cell survival (Dluzen 
and others 2011). In the future, we may see ATF5 inhibitors used to treat breast cancer, as 
inhibition of ATF5 leads to cell death in breast cancer cells but not human breast epithelial 
cells (HBEC’s) (Dluzen and others 2011). To this end, we have recently found that Hsp70 
interacts with the N-terminal of ATF5 and protects ATF5 from both caspase- and 
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proteosome-dependent protein degradation (Li and others, 2011). The next step will involve 
using in vivo studies to determine the efficacy and toxicity of ATF5 inhibitors as treatments 
for breast cancer. 
10. CREB 
Similar to ATF5, CREB can contribute to malignancy of the breast. Importantly, CREB 
induces the transcription of aromatase in breast adipose mesenchymal cells (Brown and 
Simpson 2010). Increased levels of aromatase will lead to increased estrogen levels, which 
have been implicated in breast cancer. In fact, aromatase inhibitors, such as exemestane and 
anastrazole, are currently used to treat breast cancer (Goodman and others 2006). As an 
example of positive feedback regulation, estrogen causes CREB to bind and activate the 
cyclin D1 promoter (Castro-Rivera, Samudio, Safe 2001). By activating cyclin D1, which 
causes cells to progress through the cell cycle, activation of CREB may further contribute to 
carcinogenesis. In addition, dominant negative CREB has been shown to block the 
transcription of bcl-2 in MCF7 cells (Dong and others 1999). Since bcl-2 blocks apoptosis, this 
implicates CREB as being proto-oncogenic. Although good in vitro studies have been done 
on the role of CREB in breast cancer, in vivo studies are needed to confirm its status as a 
transcription factor that supports tumor growth. 
11. Conclusions 
A host of transcription factors regulate breast cancer, acting as both oncogenes and tumor 
suppressors. The ATF/CREB family is an example of a group of transcription factors 
involved in breast cancer development, with some family members leading to breast cancer 
pathogenesis and some blocking it. Therapeutic approaches that target members that are 
oncogenic may lead to the next generation of breast cancer therapies. A drug that inhibits 
those three genes without affecting other members of the ATF/CREB family could be 
especially powerful because it could block many downstream targets at once. An 
appropriate drug discovery screen would use luciferase assays of ATF 1-5 and CREB. 
Compounds that inhibit ATF4, ATF5, and CREB while not affecting ATF1, ATF2, and ATF3 
would be considered hits. The screen could initially compare a highly metastatic breast 
cancer cell line, such as 410.4 cells to a normal mammary epithelial cell line, such as HC11 
cells. The screen would then be confirmed in both ER+ (MCF7) and ER- (MDA-MB-231) cells. 
Such a screen could lead to efficacious new breast cancer therapeutics with relatively little 
toxicity. 
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13. Abbreviations 
Acetyl-CoA, acetyl coenzyme A; ATF/CREB, activating transcription factor/cyclic AMP 
response element binding; BARD1, BRCA1 associated RING domain 1; Bcl-2, B-cell 
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CLL/lymphoma 2; BRCA1, breast cancer 1, early onset; BRCA2, breast cancer 2, early onset; 
BSP, integrin-binding sialoprotein; C/EBPǃ, CCAAT/enhancer binding protein, beta; 
C/EBPǄ, CCAAT/enhancer binding protein, gamma; CHOP, DNA-damage-inducible 
transcript 3; CREM, cyclic AMP responsive element modulator; CYP1B1, cytochrome P450, 
family 1, subfamily B, polypeptide 1; CYP2B6, cytochrome P450, family 2, subfamily B, 
polypeptide 6; EGFR, epidermal growth factor receptor; Egr-1, early growth response 1; 
ELF3, E74-like factor 3 (ets domain transcription factor, epithelial specific); ER, estrogen 
receptor; ETS1, v-ets erythroblastosis virus E26 oncogene homolog 1 (avian); GADD34, 
protein phosphatase 1, regulatory (inhibitor) subunit 15A; GATA3, GATA binding protein 3; 
HB-EGF, heparin-binding EGF-like growth factor; HER2, v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); HIF-1, 
hypoxia inducible factor 1; Hsp27, heat shock protein 27; Hsp70, heat shock protein 70; 
hTERT, human telomerase reverse transcriptase; ICAM-1, intercellular adhesion molecule 1; 
ID1, inhibitor of DNA binding 1, dominant negative helix-loop-helix protein; IRS-1, insulin 
receptor substrate 1; KLF10, Kruppel-like factor 10; LAMP3, lysosomal-associated 
membrane protein 3; MAX, MYC associated factor X; Mcl-1, myeloid cell leukemia sequence 
1 (BCL2-related); MMP1, matrix metallopeptidase 1 (interstitial collagenase); MMP2, matrix 
metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase); MMP3, 
matrix metallopeptidase 3 (stromelysin 1, progelatinase); MMP9, matrix metallopeptidase 9 
(gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); MTA1, metastasis associated 1; 
MYB, v-myb myeloblastosis viral oncogene homolog (avian); MYC, v-myc 
myelocytomatosis viral oncogene homolog (avian); NADPH, nicotinamide adenine 
dinucleotide phosphate; NF-κB, nuclear factor of kappa light polypeptide gene enhancer in 
B cells; PDEF, SAM pointed domain containing ets transcription factor; PEA3, ets variant 4; 
PEG10, paternally expressed 10; RANKL, tumor necrosis factor (ligand) superfamily, 
member 11; SGK, serum/glucocorticoid regulated kinase; STAT3, signal transducer and 
activator of transcription 3 (acute-phase response factor); STAT6, signal transducer and 
activator of transcription 6, interleukin 4-induced; TGFǃ, transforming growth factor, beta; 
TRB3, tribbles homolog 3 (Drosophila); VEGF, vascular endothelial growth factor. 
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